ATR inhibitor 2

• CAT Number: I015464
• CAS Number: 1613191-99-3
• Molecular Formula: C₂₅H₂₉F₂N₉O₃
• Molecular Weight: 541.55
• Purity: ≥95%
• IUPAC Name: 2-amino-6-fluoro-N-[5-fluoro-4-[4-[4-(oxetan-3-yl)piperazine-1-carbonyl]piperidin-1-yl]pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
• InChI: InChI=1S/C25H29F2N9O3/c26-16-9-30-23-20(22(28)32-36(23)12-16)24(37)31-19-11-29-10-18(27)21(19)34-3-1-15(2-4-34)25(38)35-7-5-33(6-8-35)17-13-39-14-17/h9-12,15,17H,1-8,13-14H2,(H2,28,32)(H,31,37)
• InChIKey: QAYHKBLKSXWOEO-UHFFFAOYSA-N
• SMILES: C1CN(CCC1C(=O)N2CCN(CC2)C3COC3)C4=C(C=NC=C4NC(=O)C5=C6N=CC(=CN6N=C5N)F)F

VX-803 (Cat No.:I015464), also known as ATRinhibitor2, is an ATP-competitive, orally active, and selective ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor with a Ki value of less than 150pM. VX-803(M4344) can effectively inhibit ATR-driven phosphorylated checkpoint kinase-1(P-Chk1) phosphorylation with an IC50 value of 8nM. VX-803(M4344) has potential antitumor activity.

Reference

[1]. Frank T. Zenke, et al. Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy. Experimental and Molecular Therapeutics.[2]. Gorecki L, et al. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. Pharmacol Ther. 2020 Feb 26:107518.